AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03051399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EpiCor
Description: The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.
Study NCT02939339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (real)
Description: a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
Study NCT02939339 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: continuous theta burst stimulation (sham)
Description: a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
Study NCT03538691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Administered as tablets.
Study NCT03538691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Description: Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.
Study NCT00303472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study NCT02223910 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Neurofeedback training of functional connectivity
Study NCT02223910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback training of functional connectivity
Study NCT02655289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modulated TENS
Description: * Frequency: 100 Hz~* Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~* Mode: intensity modulation (40% decrease every 0.5 seconds)~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)
Study NCT02655289 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: * Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~* Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~* Mode: continuous~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)
Study NCT02102347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Study NCT02102347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Study NCT02102347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy
Study NCT02102347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy
Study NCT03816618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medihoney Gel in A Tube
Description: TREATMENT1
Study NCT03816618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogel
Description: PURLOIN GEL
Study NCT03816618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fucidin Ointment
Description: FUCIDIN ANTIBIOTIC OINTMENT 10%
Study NCT02642783 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Descriptive analysis
Description: subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
Study NCT02642783 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: acceptability test
Description: subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
Study NCT02831946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MODIFIED VICRYL PLUS
Description: closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
Study NCT02831946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMABOND GLUE
Description: closing the intra-cuticular layer with Dermabond glue
Study NCT00638092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium iodide
Description: sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
Study NCT00638092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
Study NCT01533948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Given PO
Study NCT01533948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00547157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Arm 2 consists of panitmumab plus RT
Study NCT00547157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin
Study NCT02440048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bond Apatite synthetic bone substitute
Description: Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
Study NCT02440048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioOss bovine bone substitute
Description: To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
Study NCT03070756 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Minimal-Intervention - Specification of device settings
Description: - device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration \<=15 min, softPAP Level is selected based on patient comfort
Study NCT01504672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: In the intervention, the pharmacist will evaluate:~* Is there an indication for the drug?~* Has the drug desired effect?~* Is the dose correct and dosing scheme correct?~* Side effects, contraindications, inappropriate drugs~* Interactions~* Treatment time~* Cost effectiveness~* Adherence to recommendation list~* Problems with handling the drugs (for example crushing of the tablets)~* Untreated indication~* Double medications~* Administration of drugs
Study NCT00423358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Ergocalciferol 50,000 IU loading dose then twice monthly for one year
Study NCT00423358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT02950922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-501 0.2% ointment
Study NCT02950922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-501 0.5% ointment
Study NCT02950922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Placebo comparator
Study NCT02976402 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Postoperative RT consisting in:~* 31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~* 32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week
Study NCT01090141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: 100 mg IV infusion over 1 hour
Study NCT01090141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: 300 mg IV infusion over 1 hour
Study NCT00135590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein pulse-feeding
Description: Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
Study NCT00135590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spread diet
Description: Dietary protein was spread over the four meals.
Study NCT00679224 — intervention group
Intervention type: DRUG
Intervention: ambrisentan
Description: ambrisentan
Study NCT04392024 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triumf
Description: Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.
Study NCT03923517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHAPSODY online program and MEET online sessions
Description: internet-based information and skill-building program (RHAPSODY) specifically developed for family carers of care recipients with young onset dementia (Kurz, et al., 2016).~MEET is a software for online meetings.
Study NCT03689751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSCS Video
Description: LSCS video created depicting the patient journey for elective LSCS patients.
Study NCT03689751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TVT/TOT Video
Description: TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
Study NCT03285607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCS110
Description: -MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor
Study NCT03285607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: -Standard of care
Study NCT03285607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Standard of care
Study NCT03285607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -Standard of care
Study NCT03285607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate
Description: -Time of enrollment and at time of surgery
Study NCT03285607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Description: -Time of enrollment and at time of surgery
Study NCT03285607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor tissue
Description: -Time of enrollment and at time of surgery
Study NCT01703728 — intervention group
Intervention type: OTHER
Intervention: Highly purified menotropin (HP- hMG) treatment
Description: No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
Study NCT03236532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine and exercise
Study NCT03236532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin and exercise
Study NCT01750970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic resection under blue light (Hexvix®)
Description: Endoscopic resection
Study NCT01750970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic resection under blue light (Hexvix®)
Description: Endoscopic resection
Study NCT00589303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved rate and rhythm control drugs
Description: Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~* metoprolol~* atenolol~* carvedilol~Calcium Channel Blocker:~* verapamil~* diltiazem~Rhythm Control:~* procainamide~* quinidine~* disopyramide~* propafenone~* flecainide~* sotalol~* dofetilide~* amiodarone
Study NCT00589303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Node ablation and device implant
Description: Pacing Systems:~* Enpusle Premarket Approval Number (PMA#) P980035~* EnRhythm PMA# P980035~* Adapta PMA# P980035~Cardiac Resynchronization Therapy (CRT) Pacing Systems:~- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031~Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:~* EnTrust PMA# P980016~* Virtuoso PMA# P980016~ICD CRT Pacing Systems:~* InSync Maximo PMA# P980016~* InSync Sentry PMA# P890003~* Concerto PMA# P980016
Study NCT00790387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
Study NCT00790387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Study NCT00790387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Study NCT01618370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
Study NCT01853501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: ADSC ovary injection
Study NCT00534638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Intramuscular injection, 3 doses
Study NCT00534638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Intramuscular injection, 3 doses
Study NCT00534638 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular injection, 3 doses
Study NCT01551797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 500 mg
Description: Standard Paracetamol formulation
Study NCT01551797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Description: Paracetamol Sustained Release formulation
Study NCT01551797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 750 mg
Description: Paracetamol Sustained Release formulation
Study NCT04962529 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
Study NCT01076244 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally Invasive Lumbar Decompression
Description: This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
Study NCT03613389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral topical vitamin E
Description: Vitamin E is an antioxidant agent which may limit tissue damage from free oxygen radicals and, thus, may reduce the severity of mucositis during cancer treatments and protect cell membranes from radiation damage (Alterio et al., 2007). It has a very low toxicity and is generally well-tolerated (Geeraert et al., 2015).
Study NCT01561677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway pressure-RESPIRONICS
Description: obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap
Study NCT01561677 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Continuous Positive Airway pressure-RESPIRONICS
Description: inefficient Continuous Positivie Airway pressure
Study NCT04802889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scanning electron microscopy
Description: scanning electron microscopy of the сentral retina and preretinal structures
Study NCT02271984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.
Study NCT02271984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study NCT02271984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study NCT02271984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study NCT02271984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study NCT02271984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2499550A
Description: Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
Study NCT02439788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg/m2/day x 2 days; for patients \<12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
Study NCT02439788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day x 3 days; for patients \<12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
Study NCT02439788 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GINAKIT Cells
Description: * Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future.
Study NCT03494049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Veil sparring HoLEP
Description: Early mucosal incision; lateral to the Veru and proximal to the apical bulge of the adenoma, followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring.
Study NCT03494049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard HoLEP
Description: Holmium laser enucleation of the prostate in the standard approach described by Elhilali et al 2010
Study NCT01457638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior turbinate surgery
Description: During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
Study NCT01457638 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No iInferior turbinate surgery
Description: During rhinoseptoplasty no intervention is done in inferior turbinates
Study NCT04342143 — intervention group
Intervention type: DEVICE
Intervention: Blood pressure and ultrasound assessment
Description: No intervention. Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will be asked to visit the lab on four separate occasions; the first two sessions will involve triplicated measures of carotid-femoral PWV (cfPWV), brachial-femoral PWV (bfPWV), brachial-ankle PWV (baPWV), femoral-ankle PWV (faPWV) and TT by the Vicorder in both seated and supine position. The SphygmoCor will also be used to assess cfPWV in both seated and supine. During the third and fourth sessions individuals will be randomised into either a supine or seated position. A 3 lead ECG will be attached and ultrasound video clips will be taken at the carotid, brachial, femoral and posterior tibial artery on both the symptomatic and asymptomatic sides to look at stiffness and blood velocity. Following this, the Vicorder will be used to look at cfPWV, bfPWV, baPWV, faPWV and TT on both sides.
Study NCT02772939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Description: Catheter based renal sympathetic denervation for therapy resistant arterial hypertension